SHALLCROSS STEVEN A (CEO and CFO) purchased 13.5% of their position (25K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $26.1K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 2/13/2023ACC: 0001104659-23-018901
DirectorOfficer· CEO and CFO
Since Dec 2018
+25K
Net shares
Net buyer
$26.1K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
25K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+25K
Price / share
$1.04
Trade value
$26.07K
% of position
13.5%
2/10/2023
185K→210K
Total
Net shares
+25K
Net value
$26.07K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/10/2023 | P · Purchase | +25K | $1.04 | $26.07K | 13.5% | 185K | 210K |
| Total | +25K | $26.07K | ||||||
Derivative Transactions0
No derivative transactions reported